NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the
15th Annual Bio CEO & Investor Conference in New York on
Monday, February 11, 2013 at 10:30 a.m. ET and the Leerink Swann Global
Healthcare Conference on Thursday, February 14, 2013 at 8:00 AM ET.
Presentations will be available as live webcasts with replays available
approximately three hours after the presentations have concluded.
Interested parties may access the webcast from the investors' calendar
of events page on the NPS website at http://www.npsp.com/calendar.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing
orphan products to patients with rare disorders and few, if any,
therapeutic options. The company's lead product, Gattex®
0.05 mg/kg/d (Teduglutide [rDNA origin]) for Injection is FDA-approved
for the treatment of adult patients with short bowel syndrome (SBS) who
are dependent on parenteral support. NPS is also developing Natpara®
(rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects
to submit its Biologic License Application (BLA) to the FDA in mid-2013.
NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790
and NPSP795, with potential application in rare disorders involving
increased calcium receptor activity, such as autosomal dominant
hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary
programs with a royalty-based portfolio of products and product
candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen
Pharmaceuticals, Kyowa Hakko Kirin, and Takeda GmbH.
[ Back To NFVZone's Homepage ]